×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AGIO – agios pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AGIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
02:48 pm
agio
Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.
Low
Report
Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.
3/4
09:21 am
agio
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets [Yahoo! Finance]
Low
Report
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets [Yahoo! Finance]
3/4
09:00 am
agio
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
Medium
Report
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
3/3
09:00 am
agio
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
Medium
Report
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
3/2
09:22 pm
agio
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]
3/2
07:35 am
agio
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates [Yahoo! Finance]
Low
Report
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates [Yahoo! Finance]
3/2
07:00 am
agio
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
Low
Report
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
2/14
06:37 pm
agio
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2026
06:30 am
AGIO
agios pharmaceuticals, inc.
MISS
Report
1.0%
agios pharmaceuticals, inc.
10/30/2025
06:30 am
AGIO
agios pharmaceuticals, inc.
BEAT
Report
2.9%
agios pharmaceuticals, inc.
7/31/2025
06:30 am
AGIO
agios pharmaceuticals, inc.
MISS
Report
-0.5%
agios pharmaceuticals, inc.
5/1/2025
06:30 am
AGIO
agios pharmaceuticals, inc.
BEAT
Report
1.1%
agios pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/5
04:28 pm
agio
Form 144 AGIOS PHARMACEUTICALS, Filed by: Viswanadhan Krishnan
Low
Report
Form 144 AGIOS PHARMACEUTICALS, Filed by: Viswanadhan Krishnan
3/5
04:08 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Mar 03 Filed by: Washburn Theodore James Jr.
Low
Report
Form 4 AGIOS PHARMACEUTICALS, For: Mar 03 Filed by: Washburn Theodore James Jr.
3/3
04:21 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Goff Brian
Low
Report
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Goff Brian
3/3
04:21 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Burns James William
Low
Report
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Burns James William
3/3
04:21 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Gheuens Sarah
Low
Report
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Gheuens Sarah
3/3
04:18 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Washburn Theodore James Jr.
Low
Report
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Washburn Theodore James Jr.
3/3
04:18 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Jones Cecilia
Low
Report
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Jones Cecilia
3/3
04:18 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Milanova Tsveta
Low
Report
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Milanova Tsveta
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/13
Form 8-K AGIOS PHARMACEUTICALS, For: Jan 13
8.7%
11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%
9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%
10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%
12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%
6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%
2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%
7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%
5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%
4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%
11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%
9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%
10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%
12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%
6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%
2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%
7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%
5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%
4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%
TOP News Decliners
5/1
Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $72.00 price target on the stock.
-13.0%
8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%
12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%
5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%
4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%
10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%
9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%
2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%
2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%
8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%
12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%
5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%
4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%
10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%
9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%
2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%
2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: